Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress
PRNewsWire
·
2026-05-18
·
via The Tech Buzz - Press Releases
SAN MATEO, Calif., May 18, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pio…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。